Lipid Effects of Peroxisome Proliferator-Activated Receptor-&Dgr; Agonist GW501516 in Subjects With Low High-Density Lipoprotein Cholesterol: Characteristics of Metabolic Syndrome

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Arteriosclerosis, Thrombosis and Vascular Biology

• Publication date

  2012-09-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1161/ATVBAHA.112.247890PMID 22814748
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Prospective study of coronary heart disease vs. HDL2, HDL3, and other lipoproteins in Gofman's Livermore Cohort.

  2011cited by this paper
• Overproduction of Very Low–Density Lipoproteins Is the Hallmark of the Dyslipidemia in the Metabolic Syndrome

  2008cited by this paper
• Activation of Peroxisome Proliferator–Activated Receptor (PPAR)δ Promotes Reversal of Multiple Metabolic Abnormalities, Reduces Oxidative Stress, and Increases Fatty Acid Oxidation in Moderately Obese Men

  2008influential reference
• Peroxisome proliferator‐activated receptor‐δ induces insulin‐induced gene‐1 and suppresses hepatic lipogenesis in obese diabetic mice

  2008cited by this paper
• PPARdelta increases expression of the human apolipoprotein A-II gene in human liver cells.

  2008cited by this paper
• PPARδ increases expression of the human apolipoprotein A-II gene in human liver cells

  2008cited by this paper
• Apolipoprotein A-II Is Inversely Associated With Risk of Future Coronary Artery Disease

  2007cited by this paper
• New Therapeutic Target for Metabolic Syndrome: PPARδ

  2007cited by this paper
• Apolipoprotein AII Is Inversely Associated With Risk of Future Coronary Artery Disease

  2007cited by this paper
• New therapeutic target for metabolic syndrome: PPARdelta.

  2007cited by this paper
• Peroxisome proliferator-activated receptor-δ, a regulator of oxidative capacity, fuel switching and cholesterol transport

  2006cited by this paper
• The rationale for using apoA‐I as a clinical marker of cardiovascular risk

  2006cited by this paper
• Triglyceride:High-Density Lipoprotein Cholesterol Effects in Healthy Subjects Administered a Peroxisome Proliferator Activated Receptor &dgr; Agonist

  2006cited by this paper
• Regulation of Muscle Fiber Type and Running Endurance by PPARδ

  2004cited by this paper
• Activation of peroxisome proliferator-activated receptor δ induces fatty acid β-oxidation in skeletal muscle and attenuates metabolic syndrome

  2003cited by this paper
• Peroxisome-proliferator-activated receptor delta activates fat metabolism to prevent obesity.

  2003cited by this paper
• Peroxisome-Proliferator-Activated Receptor δ Activates Fat Metabolism to Prevent Obesity

  2003cited by this paper
• Low-Density Lipoprotein Size and Cardiovascular Disease: A Reappraisal

  2003cited by this paper
• Apolipoprotein A-II, HDL metabolism and atherosclerosis.

  2002cited by this paper
• Why Cholesterol Measurements May be Misleading about Lipoprotein Levels and Cardiovascular Disease Risk – Clinical Implications of Lipoprotein Quantification Using NMR Spectroscopy/Warum Cholesterin bei der Beurteilung von Lipoprotein-Konzentrationen und kardiovaskulärem Risiko in die Irre führt – K

  2002cited by this paper
• Measurement of lipoprotein subclass profiles by nuclear magnetic resonance spectroscopy.

  2002cited by this paper
• Peroxisome proliferator-activated receptors: from genes to physiology.

  2001cited by this paper
• A selective peroxisome proliferator-activated receptor δ agonist promotes reverse cholesterol transport

  2001cited by this paper
• Coronary Heart Disease Prediction From Lipoprotein Cholesterol Levels, Triglycerides, Lipoprotein(a), Apolipoproteins A-I and B, and HDL Density Subfractions: The Atherosclerosis Risk in Communities (ARIC) Study

  2001cited by this paper
• The PPARs: from orphan receptors to drug discovery.

  2000cited by this paper
• Peroxisome proliferator activated receptor agonists.

  1997cited by this paper
• Peroxisome proliferator-activated receptor agonists.

  1997cited by this paper

• PPARδ: An Underappreciated Tumor Accelerator in Pancreatic Ductal Adenocarcinoma.

  2026cites this paper
• Pancreatic inflammation induced by hypothyroidism in female rabbits is associated with cholesterol accumulation and a reduced expression of CYP51A1, FXRβ, and PPARβ/δ

  2024cites this paper
• The Versatile Role of Peroxisome Proliferator-Activated Receptors in Immune-Mediated Intestinal Diseases

  2024cites this paper
• GW0742 as a Potential TRα and TRβ Antagonist Reduces the Viability and Metabolic Activity of an Adult Granulosa Tumour Cell Line and Simultaneously Upregulates TRβ Expression

  2024cites this paper
• PPARβ/δ as a promising molecular drug target for liver diseases: A focused review.

  2024cites this paper
• Activation of PPARδ in bone marrow endothelial progenitor cells improves their hematopoiesis-supporting ability after myelosuppressive injury.

  2024cites this paper
• Edible Bird’s Nest Effectively Attenuates Atherosclerosis through Modulation of Cholesterol Metabolism via Activation of PPARγ/LXRα Signaling Pathway In Vivo

  2023cites this paper
• Crosstalk between Lipids and Non-Alcoholic Fatty Liver Disease

  2023cites this paper
• Macrophage fatty acid oxidation in atherosclerosis.

  2023cites this paper
• Discovery and structure-activity relationship study of 2-piperazinyl-benzothiazole derivatives as potent and selective PPARδ agonists.

  2023cites this paper
• Targeted therapeutics and novel signaling pathways in non-alcohol-associated fatty liver/steatohepatitis (NAFL/NASH)

  2022cites this paper
• PPAR-δ: A key nuclear receptor in vascular function and remodeling.

  2022cites this paper
• Abnormal Metabolism in the Progression of Nonalcoholic Fatty Liver Disease to Hepatocellular Carcinoma: Mechanistic Insights to Chemoprevention

  2021cites this paper
• Targeting Energy Expenditure—Drugs for Obesity Treatment

  2021cites this paper
• Co-Incubation with PPARβ/δ Agonists and Antagonists Modeled Using Computational Chemistry: Effect on LPS Induced Inflammatory Markers in Pulmonary Artery

  2021cites this paper
• Modelling the effects of PPARβδ of innate inflammatory responses in lung tissues

  2020cites this paper
• PPARs as Nuclear Receptors for Nutrient and Energy Metabolism

  2019cites this paper
• The Future Directions of Childhood Obesity and Clinical Management

  2019cites this paper
• Exploration and Development of PPAR Modulators in Health and Disease: An Update of Clinical Evidence

  2019cites this paper
• Nutritional strategies to modulate inflammation pathways via regulation of peroxisome proliferator-activated receptor β/δ.

  2019cites this paper
• The association between peroxisome proliferator-activated receptor Δ rs3777744, rs3798343, and rs6922548 and coronary artery disease

  2018cites this paper
• PPARβ/δ a potential target in pulmonary hypertension blighted by cancer risk

  2018cites this paper
• Comparative Evaluation of Gemcabene and Peroxisome Proliferator–Activated Receptor Ligands in Transcriptional Assays of Peroxisome Proliferator–Activated Receptors: Implication for the Treatment of Hyperlipidemia and Cardiovascular Disease

  2018cites this paper
• Thyroid Hormone Receptor Antagonists: From Environmental Pollution to Novel Small Molecules.

  2018cites this paper
• Ginsenoside Rg1 augments oxidative metabolism and anabolic response of skeletal muscle in mice

  2018cites this paper
• PPARβ/δ: A Key Therapeutic Target in Metabolic Disorders

  2018cites this paper
• Antihypertensive effects of peroxisome proliferator-activated receptor-β/δ activation.

  2017cites this paper
• REVIEW Small Vessels-Big Problems: Novel Insights into Microvascular Mechanisms of Diseases Antihypertensive effects of peroxisome proliferator-activated receptor- (cid:2) / (cid:3) activation

  2017cites this paper
• PPARs in obesity-induced T2DM, dyslipidaemia and NAFLD

  2017cites this paper
• Intestinal PPARδ protects against diet-induced obesity, insulin resistance and dyslipidemia

  2017cites this paper
• The selective peroxisome proliferator–activated receptor‐delta agonist seladelpar reverses nonalcoholic steatohepatitis pathology by abrogating lipotoxicity in diabetic obese mice

  2017cites this paper
• The Non-Genomic Effects of the PPARβγ agonist GW0742 on STZ treated rat aorta

  2017cites this paper
• In silico modelling of prostacyclin and other lipid mediators to nuclear receptors reveal novel thyroid hormone receptor antagonist properties.

  2016cites this paper
• Combinatorial therapeutic activation with heparin and AICAR stimulates additive effects on utrophin A expression in dystrophic muscles.

  2016cites this paper
• Current and future trends in the lipid lowering therapy

  2016cites this paper
• Unraveling the Effects of PPARβ/δ on Insulin Resistance and Cardiovascular Disease.

  2016cites this paper
• A selective peroxisome proliferator-activated receptor δ agonist PYPEP suppresses atherosclerosis in association with improvement of the serum lipoprotein profiles in human apolipoprotein B100 and cholesteryl ester transfer protein double transgenic mice.

  2016influential citation
• Transcriptional control of physiological and pathological processes by the nuclear receptor PPARβ/δ.

  2016cites this paper
• Nuclear Receptor Modulation for the Treatment of Nonalcoholic Fatty Liver Disease

  2016cites this paper
• Apoptotic effect of the selective PPARβ/δ agonist GW501516 in invasive bladder cancer cells

  2016cites this paper
• Nuclear receptors and AMPK: can exercise mimetics cure diabetes?

  2016cites this paper
• Vascular smooth muscle cell dysfunction in diabetes: nuclear receptors channel to relaxation.

  2016cites this paper
• Novel investigational drugs mimicking exercise for the treatment of cachexia

  2016cites this paper
• Trends in Endocrinology and Metabolism Unravelling the effects of PPARbeta/delta on insulin resistance and CVD

  2016cites this paper
• Activation of Peroxisome Proliferator–Activated Receptor-&dgr; as Novel Therapeutic Strategy to Prevent In-Stent Restenosis and Stent Thrombosis

  2016cites this paper
• Interaction Between Peroxisome Proliferator Activated Receptor δ and Epithelial Membrane Protein 2 Polymorphisms Influences HDL‐C Levels in the Chinese Population

  2016influential citation
• Prostaglandins and Other Lipid Mediators riginal research article n silico modelling of prostacyclin and other lipid mediators to nuclear eceptors reveal novel thyroid hormone receptor antagonist roperties oelia

  2015cites this paper
• Association and Interaction of PPARα, δ, and γ Gene Polymorphisms with Low-Density Lipoprotein-Cholesterol in a Chinese Han Population

  2015cites this paper
• Linking Induction and Transrepression of PPARβ/δ with Cellular Function

  2015influential citation
• In vitro evaluation of dual agonists for PPARγ/β from the flower of Edgeworthia gardneri (wall.) Meisn.

  2015cites this paper
• Role of ApoA1 on High-Density Lipoprotein: an intervention with plant sterols in patients with hypercholesterolemia

  2015cites this paper
• Regulating PPARδ signaling as a potential therapeutic strategy for skeletal muscle disorders in heart failure.

  2015cites this paper
• Minireview: nuclear receptor regulation of osteoclast and bone remodeling.

  2015cites this paper
• PPAR-β/δ activation promotes phospholipid transfer protein expression.

  2015cites this paper
• Role of ApoA1 on high-density lipoprotein: an intervention with plant sterols in patients with hypercholesterolemia.

  2014cites this paper
• Role of selective peroxisome proliferator‐activated receptor modulators in managing cardiometabolic disease: tale of a roller‐coaster

  2014cites this paper
• Peroxisome proliferator activated receptor-δ: the middle child vies for attention.

  2014cites this paper
• The therapeutic potential of skeletal muscle plasticity in Duchenne muscular dystrophy: phenotypic modifiers as pharmacologic targets

  2014cites this paper
• Metabolic modulators of the exercise response: doping control analysis of an agonist of the peroxisome proliferator-activated receptor δ (GW501516) and 5-aminoimidazole-4-carboxamide ribonucleotide (AICAR).

  2014cites this paper
• Turn up the power – pharmacological activation of mitochondrial biogenesis in mouse models

  2014cites this paper
• New peroxisome proliferator-activated receptor agonists: potential treatments for atherogenic dyslipidemia and non-alcoholic fatty liver disease

  2014cites this paper
• Revista6Vol88ingles_Layout 1

  2014cites this paper
• Peroxisome proliferator-activated receptor &dgr;: a multifaceted metabolic player

  2013cites this paper
• Pleiotropic effects of peroxisome proliferator-activated receptor γ and δ in vascular diseases.

  2013cites this paper
• Harnessing the benefits of PPARβ/δ agonists.

  2013influential citation
• PPARβ/δ governs Wnt signaling and bone turnover

  2013cites this paper
• Novel benefits of peroxisome proliferator-activated receptors on cardiovascular risk

  2013cites this paper
• Peroxisome proliferator-activated receptor agonists (PPARs): a promising prospect in the treatment of psoriasis and psoriatic arthritis

  2013cites this paper
• Mechanisms governing the health and performance benefits of exercise

  2013cites this paper
• Regulation of Lipid Homeostasis, Inflammatory Signalling and Atherosclerosis by the Peroxisome Proliferator-Activated Receptor Delta

  2013influential citation
• Peroxisome proliferator-activated receptor agonists (PPARs): a promising prospect in the treatment of psoriasis and psoriatic arthritis * Os receptores ativados pelo proliferador de peroxissoma (PPAR): uma perspectiva promissora na condução da psoríase e artrite psoriásica

  2013cites this paper
• PPARδ binding to heme oxygenase 1 promoter prevents angiotensin II-induced adipocyte dysfunction in Goldblatt hypertensive rats

  2013cites this paper
• Current world literature.

  2013cites this paper
• Current world literature.

  2013cites this paper
• Peroxisome proliferator-activated receptor delta and cardiovascular disease.

  2013cites this paper